<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715022</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00146744</org_study_id>
    <nct_id>NCT04715022</nct_id>
  </id_info>
  <brief_title>Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)</brief_title>
  <official_title>Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of research is to examine and understanding the development of hypertension&#xD;
      in obese adults with insulin resistance. Findings from our studies will identify unique&#xD;
      mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the&#xD;
      excessively high prevalence of hypertension and risk for cardiovascular disease (CVD).&#xD;
&#xD;
      This study is testing the health of the blood vessels and the activity of the nerves that&#xD;
      control the blood vessels in adults with insulin resistance. The extent to which ascorbic&#xD;
      acid (Vitamin C) improves the function of the blood vessels will be determined. The primary&#xD;
      outcome is blood pressure, which is the result of blood vessel health and activity of the&#xD;
      nerves, and the reduction in blood pressure that is observed with ascorbic acid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of infusion of ascorbic acid</measure>
    <time_frame>30 minutes</time_frame>
    <description>The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of infusion of ascorbic acid</measure>
    <time_frame>60 minutes</time_frame>
    <description>The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of infusion of ascorbic acid</measure>
    <time_frame>90 minutes</time_frame>
    <description>The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of infusion of ascorbic acid</measure>
    <time_frame>120 minutes</time_frame>
    <description>The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Hypertension</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will be administered over 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ascorbic acid infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the University of Kansas (KU) Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a &quot;drip-infusion&quot; of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic acid solution (American Regent Laboratories Inc.)</intervention_name>
    <description>Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a &quot;drip-infusion&quot; of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.</description>
    <arm_group_label>Ascorbic acid infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo (saline) will be administered</description>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Obese: BMI &gt;30 m/kg2&#xD;
&#xD;
          2. Elevated insulin resistance: Homeostatic Model Assessment of Insulin Resistance&#xD;
             (HOMA-IR) &gt; 2.5 (calculation based on fasting glucose and insulin concentrations in&#xD;
             blood)&#xD;
&#xD;
          3. Middle-aged: 35-65 years&#xD;
&#xD;
          4. Participants must be willing and able to discontinue taking any vitamin C or E&#xD;
             supplements or omega-3 fatty acids beginning 2 weeks prior.&#xD;
&#xD;
          5. Able and willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diabetes mellitus: fasting glucose &lt; 1267 mg/dL and/or HbA1c &lt; 6.5%&#xD;
&#xD;
          2. Currently taking a statin or antihypertension medication&#xD;
&#xD;
          3. Hyperlipidemia: Fasting triglycerides &lt; 250 mg/dL&#xD;
&#xD;
          4. Hypertension: &lt;130/80 mmHg&#xD;
&#xD;
          5. History of heart disease (e.g., myocardial infarction, stent)&#xD;
&#xD;
          6. History of vascular disease (e.g., bypass, stroke)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth Holwerda, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seth Holwerda, PhD</last_name>
    <phone>9729223230</phone>
    <email>sholwerda@kumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Clark, MPA</last_name>
    <phone>913-945-5763</phone>
    <email>mclark16@kumc.edi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davina Clonch</last_name>
      <phone>913-226-6009</phone>
      <email>dclonch@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Gangwish</last_name>
      <phone>913-444-0949</phone>
      <email>mgangwish@kumc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Seth Holwerda PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

